• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神科医生的脂质知识概述

Lipids for psychiatrists - an overview.

作者信息

Young Ian S

机构信息

Centre for Clinical and Population Sciences, Queen's University Belfast, Belfast, UK.

出版信息

J Psychopharmacol. 2005 Nov;19(6 Suppl):66-75. doi: 10.1177/0269881105058374.

DOI:10.1177/0269881105058374
PMID:16280339
Abstract

Serum cholesterol is a major risk factor for cardiovascular disease. Total cholesterol, LDL cholesterol and triglycerides are positively related to cardiovascular disease, while HDL cholesterol has an inverse relationship. Measurement of lipids is essential in individuals with established cardiovascular disease or type 2 diabetes, and may also be carried out in healthy individuals as part of cardiovascular risk assessment. Lifestyle measures are important in cardiovascular disease prevention, but the mainstay of lipid lowering therapy is appropriate use of lipid lowering drugs. Total and LDL cholesterol are the primary targets for treatment, but consideration should also be given to raising HDL cholesterol and lowering triglycerides where appropriate. Statins are the most frequently used lipid lowering agents, but there is an important place for other drugs, including ezetimibe, fibrates and nicotinic acid.

摘要

血清胆固醇是心血管疾病的主要危险因素。总胆固醇、低密度脂蛋白胆固醇和甘油三酯与心血管疾病呈正相关,而高密度脂蛋白胆固醇则呈负相关。对于已确诊的心血管疾病或2型糖尿病患者,脂质检测至关重要,在健康个体中也可作为心血管风险评估的一部分进行检测。生活方式干预在心血管疾病预防中很重要,但降脂治疗的主要手段是合理使用降脂药物。总胆固醇和低密度脂蛋白胆固醇是主要治疗靶点,但也应酌情考虑升高高密度脂蛋白胆固醇和降低甘油三酯。他汀类药物是最常用的降脂药物,但其他药物,包括依泽替米贝、贝特类药物和烟酸,也有重要作用。

相似文献

1
Lipids for psychiatrists - an overview.精神科医生的脂质知识概述
J Psychopharmacol. 2005 Nov;19(6 Suppl):66-75. doi: 10.1177/0269881105058374.
2
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.法国全科医疗中接受降脂治疗患者的混合性血脂异常:一项观察性研究。
Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003.
3
The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.认识和治疗高密度脂蛋白胆固醇水平偏低的重要性:动脉粥样硬化管理的新时代。
Rev Cardiovasc Med. 2008 Fall;9(4):239-58.
4
Diabetic dyslipidemia: extending the target beyond LDL cholesterol.糖尿病血脂异常:将治疗目标扩展至低密度脂蛋白胆固醇之外。
Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S20-4. doi: 10.1097/01.hjr.0000368195.09485.17.
5
Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.在当代患有冠心病风险等同症的普通医疗人群中,已接受的血清脂质目标的达成程度。
Am J Cardiol. 2006 Nov 1;98(9):1231-3. doi: 10.1016/j.amjcard.2006.05.057. Epub 2006 Sep 7.
6
Pathogenesis and management of the dyslipidemia of the metabolic syndrome.代谢综合征血脂异常的发病机制与管理
Metab Syndr Relat Disord. 2009 Apr;7(2):83-8. doi: 10.1089/met.2008.0079.
7
The treatment of dyslipidemia--what's left in the pipeline?血脂异常的治疗——后续还有哪些在研项目?
ChemMedChem. 2008 Feb;3(2):206-21. doi: 10.1002/cmdc.200700165.
8
[Diabetic dyslipoproteinemia: beyond LDL].[糖尿病血脂蛋白异常:超越低密度脂蛋白]
Dtsch Med Wochenschr. 2009 May;134(20):1067-73. doi: 10.1055/s-0029-1222571. Epub 2009 May 6.
9
[Treatment of dyslipidemia in clinical practice].[临床实践中的血脂异常治疗]
Orv Hetil. 2006 Mar 5;147(9):389-94.
10
Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.2型糖尿病患者的降脂治疗:早期干预的理由
Diabetes Metab Res Rev. 2008 May-Jun;24(4):286-93. doi: 10.1002/dmrr.806.

引用本文的文献

1
A Novel Drug Delivery System: Hyodeoxycholic Acid-Modified Metformin Liposomes for Type 2 Diabetes Treatment.一种新型药物递送系统:用于 2 型糖尿病治疗的熊去氧胆酸修饰的二甲双胍脂质体。
Molecules. 2023 Mar 8;28(6):2471. doi: 10.3390/molecules28062471.
2
Phytochemical Screening and Antidiabetic, Antihyperlipidemic, and Antioxidant Properties of (Coss.) Flowers Extracts in an Alloxan-Induced Rats Model of Diabetes.(科思)花提取物在四氧嘧啶诱导的糖尿病大鼠模型中的植物化学筛选及抗糖尿病、抗高血脂和抗氧化特性
Evid Based Complement Alternat Med. 2018 Jun 24;2018:8516302. doi: 10.1155/2018/8516302. eCollection 2018.
3
Antidiabetic, antihyperlipidemic and antioxidant activities of a novel proteoglycan from ganoderma lucidum fruiting bodies on db/db mice and the possible mechanism.
灵芝子实体新型糖蛋白的降血糖、降血脂和抗氧化活性及其作用机制研究。
PLoS One. 2013 Jul 11;8(7):e68332. doi: 10.1371/journal.pone.0068332. Print 2013.